Comparative Safety and Bioequivalence of Two Treatments in the Treatment of Acne Vulgaris

NCT ID: NCT02525549

Last Updated: 2021-11-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 903 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-12-31
• Study Completion Date: 2012-08-31

Brief Summary

The purpose of this study is to compare the safety and bioequivalence of Perrigo's product to an FDA approved product for the treatment acne vulgaris.

Conditions

Acne

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Test product

Adapalene and Benzoyl Peroxide Gel

Group Type: EXPERIMENTAL

Adapalene and Benzoyl Peroxide Gel

Intervention Type: DRUG

Reference product

Adapalene and Benzoyl Peroxide Gel (Reference)

Group Type: ACTIVE_COMPARATOR

Adapalene and Benzoyl Peroxide Gel (Reference)

Intervention Type: DRUG

Placebo product

Placebo gel

Group Type: PLACEBO_COMPARATOR

Placebo gel

Intervention Type: DRUG

Interventions

Adapalene and Benzoyl Peroxide Gel

Intervention Type: DRUG

Adapalene and Benzoyl Peroxide Gel (Reference)

Intervention Type: DRUG

Placebo gel

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male and non-pregnant female subjects, 12 to 40 years of age (inclusive), with a clinical diagnosis of at least moderate facial acne vulgaris
• Inflammatory lesion (papules and pustules) count of 20 to 50 (inclusive)
• Non-inflammatory (open and closed comedones) lesion count of 25 to 100 (inclusive)
• No more than two nodulocystic lesions (i.e., nodules and cysts) on the face including those present on the nose, were enrolled.
• Subjects must also have had a Baseline IGA score of 3 or 4 on a severity scale of 0 to 4 to be enrolled.

Exclusion Criteria

• Subjects who are pregnant, nursing, or planning a pregnancy within the study participation period.
• Presence of more than 2 facial Nodulocystic lesions (i.e. nodules and cysts)
• Subjects with active cystic acne or Polycystic Ovarian Syndrome
• Presence of any other facial skin condition that, in the Investigator's opinion, might interfere with acne vulgaris diagnosis and/or evaluations (e .g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculiti s).
• Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris.
• Acne conglobata, acne fulminan s, or secondary acne (chloracne, drug-induced acne, etc.)
• Use of antipruritics including antihistamine, within 24 hours prior to all study visits (Visit l/Baseline through Visit 4).
• Use of medicated make-up throughout the study and significant change in the use of consumer products within 30 days of study entry and throughout the study (other than study supplied cleanser and lotion).
• Use within 6 months prior to baseline or during the study of oral retinoids (e.g. Accutane"') or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
• Use within 1 month prior to baseline or during the study of therapeutic vitamin D supplement (multivitamins are allowed).
• Use within 1 month prior to baseline or during the study of 1) systemic sterOids', 2) systemic antibiotics, 3) systemic treatment for acne vulgaris (other than oral retinoids which require a 6-month washout), or 4) systemic anti-inflammatory agents". (' Intranasal and inhaled corticosteroids do not require a washout and may be used throughout the study if at a stable and standard dose. "Subjects may use Acetaminophen for pain relief, as needed, throughout the study)
• Use within 14 days prior to baseline or during the study of 1) topical sterOids, 2) topical retinoids, 3) topical acne treatments including over-the-counter preparation (e.g. azelaic acid,etc.) 4)a-hydroxy/glycolic acid, 5) benzoyl peroxide, 6) topical anti-inflammatory agents, or 7) topical antibiotics.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Padagis LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

PRG-817

Identifier Type: -

Identifier Source: org_study_id